About the Company
Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PFNX News
Dyadic Announces Change in Board and Management Leadership Roles
Mr. Lucy has 33 years of experience in the biotechnology industry, including a founder of Pfenex Inc., a protein expression platform technology company that originated within The Dow Chemical ...
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M
Earlier this month, Ligand signed an agreement to merge its subsidiary Pelican Technology Holdings, Inc., with Primordial ... royalties related to Pelican (or Pfenex) Expression technology.
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc. ($516M acquisition by Ligand) and served as a Board member at Opiant Pharmaceuticals (up to $ ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
MPW Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama ...
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc. ($516M acquisition by Ligand) and served as a Board member at Opiant Pharmaceuticals (up to $500M ...
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...